VivoSeq
Other

Advanced or Metastatic NSCLC

3

Pipeline Programs↗

10

Active Trials↗

9

Companies Involved↗

Advanced or Metastatic NSCLC is an early-stage landscape with 3 programs across 9 companies. The most active players are Taiho Oncology, Inc., Innovent Biologics (Suzhou) Co. Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

43/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Taiho Oncology, Inc. logo

Taiho Oncology, Inc.

3 programs

Phase 2Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

0 programs

PreclinicalSuzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

0 programs

PreclinicalDaiichi Sankyo logo

Daiichi Sankyo

0 programs

PreclinicalS

Shanghai Shengdi Pharmaceutical Co., Ltd

0 programs

PreclinicalN

NeoTX Therapeutics Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 23

TAS6417

Taiho Oncology, Inc.

CYP Cocktail

Taiho Oncology, Inc.

Transporter Cocktail

Taiho Oncology, Inc.

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

21

clinical trials

Recruiting5 · 24%
Unknown status4 · 19%
Completed3 · 14%
Not yet recruiting3 · 14%
Withdrawn2 · 10%
Active, not recruiting2 · 10%
Other2 · 10%

Clinical Trials

Trial Activity

21 trials

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Recruiting·Daiichi Sankyo logoDaiichi Sankyo·Phase 3·NCT05215340·740 enrolled
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC
Recruiting·Suzhou Suncadia Biopharmaceuticals Co., Ltd. logoSuzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT07183189·576 enrolled
Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC
Recruiting·DDr Arvindran A/L Alaga·Phase 3·NCT07050043·123 enrolled
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Recruiting·AAllist Pharmaceuticals, Inc.·Phase 1/2·NCT05276726·104 enrolled
An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.
Recruiting·Taiho Oncology, Inc. logoTaiho Oncology, Inc.·Phase 2·NCT05967689·220 enrolled
A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC
Active, not recruiting·Suzhou Suncadia Biopharmaceuticals Co., Ltd. logoSuzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT06671379·498 enrolled
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 1/2·NCT04995523·212 enrolled
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
Not yet recruiting·SShanghai Shengdi Pharmaceutical Co., Ltd·Phase 2/3·NCT06335355·401 enrolled
Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy
Not yet recruiting·FFudan University·Phase 2·NCT07193160·45 enrolled
Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC
Not yet recruiting·—·Phase 2·NCT07432984·15 enrolled
A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
Completed·Innovent Biologics (Suzhou) Co. Ltd. logoInnovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT03150875·290 enrolled
NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
Completed·NNeoTX Therapeutics Ltd.·Phase 2·NCT04880863·38 enrolled
A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients
Completed·Innovent Biologics (Suzhou) Co. Ltd. logoInnovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT04177290·48 enrolled
A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC
Terminated·TTurning Point Therapeutics, Inc.·Phase 1·NCT04849273·11 enrolled
Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)
Terminated·UUniversity of Florida·Phase 1/2·NCT02920450·3 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)